MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis

PURPOSE: Standard therapy for myelofibrosis comprises Janus kinase inhibitors (JAKis), yet spleen response rates of 30%-40%, high discontinuation rates, and a lack of disease modification highlight an unmet need. Pelabresib (CPI-0610) is an investigational, selective oral bromodomain and extratermin...

Descripción completa

Detalles Bibliográficos
Autores principales: Mascarenhas, John, Kremyanskaya, Marina, Patriarca, Andrea, Palandri, Francesca, Devos, Timothy, Passamonti, Francesco, Rampal, Raajit K., Mead, Adam J., Hobbs, Gabriella, Scandura, Joseph M., Talpaz, Moshe, Granacher, Nikki, Somervaille, Tim C. P., Hoffman, Ronald, Wondergem, Marielle J., Salama, Mohamed E., Colak, Gozde, Cui, Jike, Kiladjian, Jean-Jacques, Vannucchi, Alessandro M., Verstovsek, Srdan, Curto-García, Natalia, Harrison, Claire, Gupta, Vikas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2023
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10642902/
https://www.ncbi.nlm.nih.gov/pubmed/36881782
http://dx.doi.org/10.1200/JCO.22.01972

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10642902/
https://www.ncbi.nlm.nih.gov/pubmed/36881782
http://dx.doi.org/10.1200/JCO.22.01972

Ejemplares similares